An interventional study of high-intensity focused ultrasound, HIFU in Prostate Cancer, sponsored by The Hospital of Vestfold. Recruiting at 1 site in Norway. Open to male participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-09-22.
Sponsored by The Hospital of Vestfold · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Prostatic Neoplasms with a site in Norway — 16 open to participants now, 27 under way, 9 of them phase 3. Prostatic Neoplasms · Norway.
Among the 85 studies in Prostatic Neoplasms with a site in Norway, this one is the 39th largest by planned enrollment of the 66 interventional ones that give a count, is one of 3 that started in 2020, is one of 23 with no phase, reaches primary completion later than 23 of the 26 other live ones, and was the 64th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →16 of the 85 studies in Prostatic Neoplasms with a site in Norway are open now. Recruiting first, the newest first:
Norwegian University of Science and Technology · Sites in Norway
Ages 50–75 · Men only · Healthy volunteers
Bayer · Sites in Norway, Belgium, Finland and 13 more countries
Ages 18+ · Men only
Merck Sharp & Dohme LLC · Sites in Norway, United States, Argentina and 32 more countries
Ages 18+ · Men only
University of Alberta · Sites in Norway, United States, Canada and 2 more countries
Ages 50–70 · Men only · Healthy volunteers
University Hospital of North Norway · Sites in Norway
Men only
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years to 80 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 15 · Phase 3 24 · Phase 4 1
First in 1995; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 383 across the 66 interventional studies, 641 across the 18 observational. Of the 53 that completed or were terminated, 17 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 85 have an industry lead sponsor. The 10 most frequent:
The Hospital of Vestfold is the lead sponsor of 16 studies on the registry; 2 are open to participants now.
The Hospital of Vestfold has 1 study filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies in Prostatic Neoplasms with a site in Norway that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT06935487Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)European Multicenter Validation of PCaVision: A Head-to-Head Diagnostic Accuracy Study Comparing Multiparametric Transrectal Ultrasound to MRI for Clinically Significant Prostate Cancer Detection | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 85 studies in Prostatic Neoplasms with a site in Norway, from their registry updates:
This tab as a report to print or save as PDF → With an account.
PSA (Prostate-specific antigen) testing has significantly increased the number of men diagnosed with prostate cancer (PCa) and especially patients with low and intermediate risk disease. The effect of radical treatment (treatment of the entire prostate gland) in these risk groups is disputable while the risk of adverse effects, with erectile dysfunction and urinary incontinence, is not. Active surveillance (AS) has been developed as an alternative to radical treatment with the aim of avoiding or delaying radical treatment by closely monitoring for signs of tumor progression. Active surveillance is regarded as the treatment of choice for low-risk prostate cancer. Focal therapy may have a crucial role in improving active surveillance protocols for patients with intermediate localized prostate cancer. Focal eradication of the index-tumor may delay or avoid indefinitely radical treatment for this patient group while significantly reducing treatment-related side effects. Improved MRI-diagnostics and MRI/ ultrasound fusion technology have optimized tumor mapping and classification and this in turn has made partial treatment of the prostate a feasible treatment option.
This study is a prospective cohort study. Patients with intermediate (high-risk) localized PCa and a visible index tumor will be treated with high-intensity focused ultrasound (HIFU).
The aim of the study is to show that there is a significant effect of focal treatment on surveillance biopsies and a reduced conversion to radical treatment, without compromising survival outcomes compared to historical controls (retrospective cohort). A cohort from the more than 450 patients included in the local AS-protocol with MRI at Vestfold hospital trust since 2009 will serve as controls.
1 Needs description It is unclear if eradication with focal treatment of the index-tumor of patients with intermediate-risk prostate cancer followed by active surveillance can reduce the need for radical, whole-gland treatment of the prostate and thereby treatment side effects. It is important for urologists and patients to know if focal treatment of prostate cancer is both a safe and effective treatment option. If proven so, focal treatment of prostate cancer can be offered as a viable, intermediate treatment option for a large group of patients who currently only have the choice between either surveillance or radical treatment.
Thus, there is an unmet need to document the outcome of focal treatment in selected patients with prostate cancer, both in terms of efficacy and safety
2.1 Hypothesis: Focal treatment of biopsy-verified, localized, MRI-visible, intermediate-risk (and high-risk fo elderly patients) prostate cancer is a safe and effective treatment option. Side effects following focal treatment are transient and mild compared to established and well-documented radical treatment options.
2.2 Aims of the study: To investigate if focal treatment of localized prostate cancer followed by MRI-supplemented active surveillance conveys sufficient tumor control to enable patients to continue indefinitely in this follow-up protocol without the need to convert to radical treatment, with none or mild side effects and without compromising oncological outcomes.
2.3 Objectives:
Primary objectives:
Secondary objectives:
Health-related quality of life
This study is a prospective, single-arm, case-control cohort study with consecutive patients with intermediate-risk, MRI-visible prostate cancer treated focally with HIFU. Participants will be compared to historical controls (patients observed with AS at SiV 2009-2017). The study design follows the international multidisciplinary consensus on trial design for focal therapy in PCa (28, 29). Patients will primarily be recruited from Vestfold-Telemark County but recruitment from other institutions in Norway is encouraged. More formal referral arrangements will be sought with Aleris (Oslo), Telemark Hospital Trust and Vestre Viken Hospital Trust.
3.1 Project arrangements, method selection and analyses From a scientific and methodological point of view a randomized, parallel-group study would have been preferable with patients receiving either AS+ (HIFU) or simple AS follow-up. However, experience from several investigative centers have shown that randomization is difficult to carry out in practice. This is because patients are aware of the HIFU possibility, and, if randomized to standard treatment, often refuse participation and demand HIFU treatment. This problem would likely be exacerbated in this study, where the control group would be offered only follow-up while study arm patients receive tumor-directed treatment with presumed few side-effects. Furthermore, the investigators have learned from own historic controls that AS is "good medicine" for merely half of the patients with intermediate-risk prostate cancer after 5 years. Since it is difficult, based on today's diagnostic tools, to identify patients that will not progress significantly over time, some form of tumor-directed treatment for all patients is sensible. Finally, patients in the historical control group were diagnosed and risk-classified by the same parameters and diagnostic tools that are currently in use. Follow-up of these patients was also very similar to the one outlined for the study patients. The investigators are not aware of any significant change in clinical practice that would suggest that the historical controls at the study institution are not representative of current patients with intermediate risk profile.
Patients who are interested in focal treatment of prostate cancer are aware of the radical treatment alternatives but are skeptical of the side effects. These patients want to know their risk of progression (metastasis and death), the risk of having to undergo radical treatment at a later stage and the short-term and long-term side effects if they choose focal treatment. We believe that this study will provide these answers for a representative Norwegian patient population.
Based on these considerations, the investigators believe that the best and most ethical design is the one proposed here, where all eligible patients receive the same treatment and are then compared to a historical control group.
Study population and Power-estimate Approximately half of active surveillance patients (50%) experience progression of their disease during 5-10 years follow-up (9). This correlates with the outcome of historical AS patients at the study institution.
The investigators estimate that only 20% of the newly diagnosed AS patients receiving HIFU will experience a progression of their disease after 10 years.
In order to detect such a reduction in progression rate, the trial will need to include 194 patients. With 20% expected dropouts, the number of patients needed to include in the HIFU cohort will be 245.
The sample size calculations are based on the ClinCalc program (http://clincalc.com/stats/samplesize.aspx).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Gleason-score:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: high-intensity focused ultrasound, HIFU
see above
Number of patients without clinically significant prostate cancer
Absence of clinically significant prostate cancer (Gleason grade ≥7A) on post-treatment systematic and targeted biopsies
Time frame: 1-10 years
Measurement of functional results
erectile function, continence, and other therapy-related complications. Questionnaire-based.
Time frame: 1-10 years
Number of patients who need repeated focal treatment
recurrence and recurrent treatment
Time frame: 1-10 years
Number of patients eligible for continuous AS+
Time frame: 1-10 years
Disease-free survival
based on repeated MRI and repeat biopsies performed on clinical/ radiological suspicion
Time frame: 1-10 years
Treatment-free survival
Time frame: 1-10 years
Overall survival
Time frame: 1-10 years
Metastasis-free survival
Time frame: 1-10 years
Number of patients who need radical (surgery or radiation), or palliative treatment (hormone therapy)
Time frame: 1-10 years
Number of patients where MRI predicted tumor recurrence/ tumor absence
MRI findings verified by biopsies
Time frame: 1-10 years
Patient Reported Outcomes Measures
Survey-based using standard questionaires
Time frame: 1-10 years
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2020 (actual). Primary completion is estimated for Sep 2030, 120 months after the start.
Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 120 months is above that.
Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Hospital of Vestfold